CLYM Climb Bio, Inc.
Price Chart
Executive Summary
Climb Bio filed an S-3 registration statement to register 11,587,000 shares of common stock for resale by selling stockholders, consisting of 9,481,000 outstanding shares and 2,106,000 shares issuable upon exercise of pre-funded warrants. The shares were issued in a private placement on April 27, 2026, which raised approximately $110.0 million in gross proceeds. The company will not receive any proceeds from the resale of shares under this prospectus, but may receive the nominal exercise price of the pre-funded warrants if exercised. This is a routine resale registration filed to fulfill contractual obligations under a registration rights agreement, not a new capital raise by the company.
Actionable Insight
This S-3 is a routine resale registration with no new dilution for the company. The overhang from the registered shares (20.2% of shares outstanding as of May 14, 2026) could create near-term selling pressure as institutional investors may reduce positions. Monitor trading volume and any prospectus supplements for actual sales by selling stockholders.
Key Facts
- S-3 registers 11,587,000 shares for resale by selling stockholders (9,481,000 outstanding + 2,106,000 pre-funded warrant shares).
- Shares were issued in a private placement on April 27, 2026, raising approximately $110.0 million in gross proceeds at $9.50 per share.
- Company will not receive any proceeds from the resale of shares under this prospectus.
- Filing is a contractual obligation under a registration rights agreement with selling stockholders.
- As of May 14, 2026, the company had 57,263,023 shares outstanding; the registered shares represent approximately 20.2% of the then-outstanding shares.
- RA Capital Healthcare Fund, L.P. is the largest selling stockholder, offering 2,106,000 shares (all pre-funded warrants).
Financial Impact
No new capital raised by the company; the private placement raised approximately $110.0 million in gross proceeds on April 27, 2026.
Risk Factors
- Potential overhang from up to 11.6M shares registered for resale could pressure the stock price.
- Selling stockholders may sell shares at any time, creating unpredictable supply.
- Pre-funded warrants (2.1M shares) could be exercised and sold, adding to selling pressure.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001193125-26-248243 |
| Document: d83073dexfilingfees.htm | 0001193125-26-248243 |
| Document: d83073dex51.htm | 0001193125-26-248243 |
| Document: d83073dex231.htm | 0001193125-26-248243 |
| Document: 0001193125-26-248243-index-headers.html | 0001193125-26-248243 |
| Document: 0001193125-26-248243-index.html | 0001193125-26-248243 |
| Document: 0001193125-26-248243.txt | 0001193125-26-248243 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
1d ago
|
8-K
| — | awaiting T+1 | — | — |
|
May 29, 2026
8d ago
|
S-3
| $11.80 $11.20 | ▼ −5.08% | ▼ −5.24% | $10.55 (−10.59%) |
|
May 7, 2026
4w ago
|
8-K
| $11.91 $11.37 | ▼ −4.53% | ▼ −5.36% | $10.55 (−11.42%) |
|
May 5, 2026
4w ago
|
8-K
| $11.45 $12.22 | ▲ +6.72% | ▲ +5.34% | $10.55 (−7.86%) |
|
Apr 28, 2026
5w ago
|
8-K
| $9.26 $8.78 | ▲ +5.18% | ▲ +5.17% | $10.55 (−13.93%) |
|
Apr 24, 2026
6w ago
|
DEFA14A
| $9.50 $9.26 | ▼ −2.53% | ▼ −2.04% | $10.55 (+11.05%) |
|
Apr 3, 2026
9w ago
|
8-K
| $6.74 $6.87 | ▲ +1.93% | ▲ +1.87% | $10.55 (+56.53%) |
|
Mar 5, 2026
13w ago
|
8-K
| $7.39 $7.18 | ▼ −2.84% | ▼ −1.53% | $10.55 (+42.76%) |
|
Mar 5, 2026
13w ago
|
Press Release
| $7.39 $7.18 | ▼ −2.84% | ▼ −1.53% | $10.55 (+42.76%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access